Cargando…

Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7)

Detalles Bibliográficos
Autor principal:	Kim, Ye An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641975/ https://www.ncbi.nlm.nih.gov/pubmed/26566503 http://dx.doi.org/10.4093/dmj.2015.39.5.444

Ejemplares similares

Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7)
por: Yagi, Shusuke, et al.
Publicado: (2015)

Letter: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)
por: Seok, Hannah
Publicado: (2015)

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52)
por: Lee, Dae Ho
Publicado: (2015)

Letter: Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes (Diabetes Metab J 2015;39:498-506)
por: Kim, Mi-Kyung
Publicado: (2016)

Letter: Prevalence of Depression and Glucose Abnormality in an Urbanizing Rural Population of Bangladesh (Diabetes Metab J 2015;39:218-29)
por: Kawada, Tomoyuki
Publicado: (2015)

Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52)
por: Suh, Sunghwan, et al.
Publicado: (2015)

Response: Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes (Diabetes Metab J 2015;39:498-506)
por: Yun, Jae-Seung, et al.
Publicado: (2016)

Response: Prevalence of Depression and Glucose Abnormality in an Urbanizing Rural Population of Bangladesh (Diabetes Metab J 2015;39:218-29)
por: Natasha, Khurshid, et al.
Publicado: (2015)

Letter: Normal Glucose Tolerance with a High 1-Hour Postload Plasma Glucose Level Exhibits Decreased β-Cell Function Similar to Impaired Glucose Tolerance (Diabetes Metab J 2015;39:147-53)
por: Kim, Hee Kyung
Publicado: (2015)

Response: Normal Glucose Tolerance with a High 1-Hour Postload Plasma Glucose Level Exhibits Decreased β-Cell Function Similar to Impaired Glucose Tolerance (Diabetes Metab J 2015;39:147-53)
por: Oh, Tae Jung, et al.
Publicado: (2015)

Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Moon, Jun Sung
Publicado: (2019)

Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
por: Kim, Jin Hwa
Publicado: (2016)

Letter: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8)
por: Beyan, Cengiz, et al.
Publicado: (2014)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
por: Nishida, Yayoi, et al.
Publicado: (2020)

Letter: Diabetic Retinopathy and Endothelial Dysfunction in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2013;37:262-9)
por: Son, Seok Man
Publicado: (2013)

Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
por: da Silva Júnior, Wellington Santana, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
por: Yousefzadeh, Pegah, et al.
Publicado: (2013)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Yagi, Shusuke, et al.
Publicado: (2015)

Associations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
por: Sato, Akihiko, et al.
Publicado: (2015)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin, Yi-Hsin, et al.
Publicado: (2019)

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
por: Gurgel Penaforte-Saboia, Jaquellyne, et al.
Publicado: (2021)

In-Vitro Studies on Selected Jordanian Plants as Dipeptidyl Peptidase-IV Inhibitors for Management of Diabetes Mellitus
por: Sewidan, Nuha, et al.
Publicado: (2020)

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
por: Wei, Xin, et al.
Publicado: (2021)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
por: Lee, Dong-Hwa, et al.
Publicado: (2021)

The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
por: Hsu, Wan-Chia, et al.
Publicado: (2022)

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
por: Yang, Tzu-Lin, et al.
Publicado: (2016)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
por: Choi, Yeo Jin, et al.
Publicado: (2019)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
por: Taylor, Olesya M., et al.
Publicado: (2020)

Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South Indian Adults with Type 2 Diabetes Mellitus
por: Sarathi, Vijaya, et al.
Publicado: (2023)

Letter: Adipokines and Insulin Resistance According to Characteristics of Pregnant Women with Gestational Diabetes Mellitus (Diabetes Metab J 2017;41:457-65)
por: Ryu, Ohk-Hyun
Publicado: (2018)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a2ddcnhm6c6trj9oosbnpldkb6